A registered product is an important milestone. It does not, by itself, establish that the right customers know about it, that a hospital has a reason to buy, or that a distributor can generate repeat demand. Before investing further in an APAC market, founders need evidence about the customer, the buying process and the route to market.
This article sets out a practical way to assess hospital and customer demand for a registered product in the MedTech and medical devices sector. It is a go-to-market planning framework, not a market-size estimate or a substitute for local regulatory advice.
1. Start with a specific customer problem
Define the clinical, workflow or operational problem the product is intended to address. Avoid beginning with a broad country list or a product-feature checklist. Identify the care setting and the type of account where the problem is most relevant.
- Which clinical application or workflow is the product designed to support?
- Which hospitals, clinics or care providers are most likely to experience the problem?
- How do those customers address it today?
- What would make them consider changing their current approach?
Separate a stated interest in the technology from evidence that the problem is important enough to justify a purchase.
2. Map the people involved in the buying decision
The person who uses or evaluates a medical device may not control the budget or approve the purchase. Map the stakeholders relevant to the product and account. These may include clinical users, department heads, biomedical engineering, procurement, finance and senior management.
For each priority account, record who has a clinical need, who can champion the product, who assesses technical requirements, who controls the budget and who authorises the purchase. Identify missing relationships rather than treating a successful demonstration as proof that the buying process is complete.
3. Understand what must happen before an order
Work backwards from the purchase decision. Ask what evidence, approvals and internal steps are required before the organisation can issue a purchase order.
- Is there an identified budget or a route to secure one?
- What clinical, technical or operational evaluation is required?
- Are procurement specifications or tender requirements involved?
- Is there an incumbent product or supplier?
- Who owns the next step, and when will it happen?
Document the evidence available for each opportunity. Label assumptions and verbal reports clearly. A hospital meeting, a positive user comment or a completed demonstration is a signal to investigate—not a confirmed order forecast.
Country examples: verify the local buying route
Public procurement is not identical across APAC. These official examples show why a country-level check matters; they are starting points for research, not a complete description of every public or private hospital's purchasing process.
- Malaysia: MDA Circular Letter No. 1/2026, effective 28 January 2026, requires new medical-device tenderers to hold a valid establishment licence, implement GDPMD and accept post-market responsibilities; healthcare institutions must verify the tenderer's licence, valid product registration and distributor appointment letter. MDA's 5 March 2026 notice sets limited transition exemptions for specified pre-28 January contracts and tenders. Read the Circular Letter and implementation notice; check the current MOH tender notices.
- Singapore: The Ministry of Finance's guidance, updated 9 September 2026, describes Small Value Purchases up to S$6,000, quotations up to S$90,000 and tender procedures above S$90,000, subject to the relevant rules and exceptions. Government opportunities are published on GeBIZ. Verify the current MOF procurement guidance and the agency's tender documents.
- New South Wales, Australia: HealthShare NSW Procurement Services manages statewide contracts including medical equipment. Its supplier guidance says the National Product Catalogue is not required before responding to a state tender, but is mandatory for most health-specific medical/surgical device and consumable contracts before the contract starts. Confirm the applicable contract and product-catalogue requirements.
For each target account, confirm whether the hospital buys through a public tender, a panel or contract, a quotation process, or a private-group approval route. Also verify who can sponsor the clinical evaluation and who controls the purchase.
4. Test distributor capability against the target customer
A distributor appointment does not automatically create market access or customer demand. Assess the partner against the accounts and buying stakeholders that matter for the product.
- Can the distributor reach the relevant hospitals and decision-makers?
- Does the team understand the product's clinical application and value proposition?
- Can it coordinate demonstrations, evaluations, quotations and follow-up?
- Can it support installation, training and after-sales requirements where relevant?
- Does it report customer-level progress, not only stock placed or opening orders?
Ask for evidence of activity at account level. Distinguish distributor inventory from end-customer sell-through, and distinguish a stated opportunity from a documented buying process.
5. Compare the product's value with current alternatives
Customers compare a proposed solution with the way they work today, including existing equipment, competing products and the option of doing nothing. Identify the factors that influence the decision in the relevant care setting.
These may include clinical suitability, workflow fit, ease of use, service coverage, training, implementation requirements, total cost and the availability of budget. Avoid relying on generic claims such as better quality or advanced technology. Connect each value statement to a customer need and evidence the buyer can assess.
6. Prioritise markets and accounts using evidence
Do not treat every country, distributor or hospital lead as equally attractive. Compare opportunities using consistent criteria, such as the relevance of the customer problem, access to buying stakeholders, clarity of the purchasing process, channel capability, competitive alternatives and the resources needed to progress.
Keep the evidence visible. A simple record can show the account, customer need, stakeholders, current alternative, buying steps, evidence received, unresolved questions, next action and owner. This makes it easier to distinguish real progress from activity that has not moved the buying decision forward.
7. Decide what to do next
Use the evidence to make one of three decisions:
Proceed: The customer need is relevant, the buying process is understood well enough to take the next step, and there is a credible route to reach and support the account.
Validate: The opportunity may be attractive, but a critical assumption remains untested. Identify the missing evidence, the person who can provide it and the next action required.
Redirect or stop: The customer need, buying conditions, competitive position or distributor capability does not currently justify further investment. Reconsider the segment, account, value proposition or route to market.
Set a review date and define what evidence would change the decision. This prevents opportunities from remaining indefinitely in a pipeline because a stakeholder once expressed interest.
From market interest to customer orders
A stronger APAC go-to-market plan starts with the customer and works backwards from the buying decision. It connects the clinical or operational need to the people who influence the purchase, the evidence procurement requires, the alternatives already in place and the distributor's ability to execute.
The objective is not to maximise meetings or market coverage. It is to focus time and resources on the opportunities with a credible path to customer orders—and to recognise early when the evidence points elsewhere.
Related Insights
← Back to all five KawaHive Insights articles
- Why MedTech Products Don’t Sell After Regulatory Approval
- Stocked by the Distributor. Bought by Whom?
- Why Hospital Demos Don’t Convert to Purchase Orders in Asia-Pacific
- Your APAC Medical Device Distributor Is Underperforming: A Decision Guide
Use the Free MedTech Prospecting Training with ICP Scorecard in KawaHive Lab to prioritise target hospitals and record evidence about account fit.
If you want structured support to prioritise accounts, buying-process gaps and distributor actions, see the 10-Week Go-to-Market Sprint. Every engagement starts with a Free 30-Minute GTM Clarity Call to assess fit; there is no obligation to proceed.
If your registered product in the MedTech and medical devices sector is attracting interest but not generating consistent orders, start with a Free 30-Minute GTM Clarity Call.